In hematopoietic stem and progenitor cells (HSPC), EZH2-inhibitors gave rise to increased NK precursors, leading to up-regulation of IL-15R (CD122) and NKG2D activated receptors, which were associated with enhanced NK cell expansion and cytotoxicity against tumor cells (Yin et al., 2015a). The gene discussed is EZH2; the disease is neoplasm.